Diffusion Pharmaceutical LLC
  • Email
  • Facebook
  • Twitter
  • Rss
  • Home
  • About
    • Introduction
    • Executive Summary
    • Management
    • Board of Directors
    • Investors
      • Investor Information Log-In
      • Potential Investor Registration
    • Intellectual Property
    • Useful Links
  • Cancer Treatment
    • Overview/The Problem
    • Treatment Resistance in Cancer
    • Tumor Sensitization and TSC
    • Preclinical Results
  • Clinical Trials
    • Clinical Trials Overview
  • Publications
    • Cancer
    • Cardiovascular and Stroke
    • Hemorrhagic Shock
    • Other
  • Programs
    • Program Overview
    • Glioblastoma Program
    • Brain Metastasis Program
    • Other Indications For TSC
  • News
    • Press Releases
    • Subscribe
  • Contact
    • Contact
    • Directions

Cancer Treatment

  • Overview/The Problem
  • Treatment Resistance in Cancer
  • Tumor Sensitization and TSC
  • Preclinical Results

Overview/The Problem

Although it was invented over one hundred years ago, radiation therapy is still the most prescribed treatment for cancer.

Despite its wide-spread use, radiation therapy has a significant limiting factor.  Tumor “hypoxia” (oxygen-deprivation) deep within tumor tissue limits radiation’s tumor-killing effectiveness.

Currently, over 750,000 people (about 65% of all cancer patients) receive radiation therapy annually in the US, with another 1.1 million in the rest of the world (ROW).

Overall, patients receive over 25 million radiation therapy treatments of cancerous tumors at about 2,000 US hospitals and freestanding radiation therapy centers annually.

  • Office: 434-220-0718
  • Contact Us
    • Facebook
    • Email
© 2012 Diffusion Pharmaceutical LLC


Charlottesville SEO